Notably, the BRD9-selective antagonist I-BRD9 has been employed in several types of cancer, including rhabdoid tumors [78], ovarian cancer [79], clear cell renal cell carcinoma (ccRCCs) [80], acute myeloid leukemia [81], and colon adenocarcinoma [72]. Here, BRD9 is linked to ovarian cancer.